Compare FEMY & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FEMY | QTTB |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.2M | 44.3M |
| IPO Year | 2021 | 2018 |
| Metric | FEMY | QTTB |
|---|---|---|
| Price | $0.50 | $7.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $5.50 | ★ $13.00 |
| AVG Volume (30 Days) | ★ 442.0K | 231.8K |
| Earning Date | 05-07-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 8.60 | ★ 136.78 |
| EPS | N/A | ★ 2.42 |
| Revenue | $1,629,108.00 | ★ $53,737,000.00 |
| Revenue This Year | $59.47 | N/A |
| Revenue Next Year | $150.54 | N/A |
| P/E Ratio | ★ N/A | $2.71 |
| Revenue Growth | ★ 51.97 | N/A |
| 52 Week Low | $0.31 | $1.38 |
| 52 Week High | $1.63 | $7.80 |
| Indicator | FEMY | QTTB |
|---|---|---|
| Relative Strength Index (RSI) | 41.82 | 69.00 |
| Support Level | $0.48 | $1.64 |
| Resistance Level | $0.58 | $7.80 |
| Average True Range (ATR) | 0.04 | 0.80 |
| MACD | -0.00 | 0.09 |
| Stochastic Oscillator | 12.87 | 82.09 |
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function.